Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria
Authors' conclusion
In patients with CKD and albuminuria, randomization to dapagliflozin was associated with modest reductions in systolic and diastolic BP.
Study context
- Population
- Adults with chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73m2) and albuminuria (urinary albumin-to-creatinine ratio (UACR) 200–5000 mg/g), with and without T2DMmedian follow-up 2.4 years
- Participants
- 4,304 adults
- Comparison
- Dapagliflozin 10 mg vs placebo once daily
- Primary endpoint
- Composite of:
- Sustained ≥50% eGFR decline
- End-stage kidney disease
- Death from a kidney or CV cause
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
SBP reduction
Reduction
3.6 mmHg
95% CI 2.8–4.4
by Week 2
Reduction
2.9 mmHg
95% CI 2.3–3.6
maintained over trial duration
Secondary outcomes
| Outcome | Reduction (mmHg) (CI) |
|---|---|
| Time-averaged DBPDapagliflozin vs Placebo · overall | 1.0 (0.6–1.4) |
| Time-averaged DBPDapagliflozin vs Placebo · with diabetes | 0.8 (0.4–1.3) |
| Time-averaged DBPDapagliflozin vs Placebo · without diabetes | 1.4 (0.7–2.1) |
Time-averaged systolic blood pressure (SBP) reduction, by diabetes status (subgroup)
- With diabetes: SBP reduction 3.2 mmHg (2.5-4.0 mmHg)
- Without diabetes: SBP reduction 2.3 mmHg (1.2-3.4 mmHg)
Primary composite and secondary endpoints, by baseline SBP and diastolic blood pressure (DBP)
- Benefits of dapagliflozin evident across the spectrum of baseline SBP and DBP
Original publication
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. Am Heart J. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →